Novartis opens Cambridge research facility
Novartis' $250 mil. investment in a 255,000 sq. ft. research facility in Cambridge, Mass. is part of the continuing trend of increasing R&D investments in the U.S. over Europe, company says. Sen. Edward Kennedy (D-Mass.) and Rep. Michael Capuano (D-Mass.) joined Novartis in a May 6 press conference announcing the opening. Research activities are scheduled to begin in the first quarter of 2003 with 400 employees, with an expansion planned to accommodate 900 scientists...
You may also be interested in...
The pharmaceutical industry is of "strategic value" to the U.S. economy and should not be jeopardized by instituting drug price controls, Novartis CEO Daniel Vasella, PhD, told the AARP International Forum on Prescription Drug Pricing Policy June 10 in Washington, D.C
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.